Addressing unmet medical needs
Our clinical-stage program, ALTB-168, is a first-in-class antibody targeting a variety of autoimmune and immune-mediated inflammatory diseases.
Our clinical-stage program, ALTB-168, is a first-in-class antibody targeting a variety of autoimmune and immune-mediated inflammatory diseases.
Pipeline
INNOVATIVE SOLUTIONS
AltruBio has built a differentiated pipeline of biologic therapies targeting diseases of inflammation with products at various stages of development.
ALTB-268
PRECLINICAL
PHASE I
PHASE IIA
PHASE IIB
PHASE III
Phase II Potency improved version of ALTB-168, Phase 1 trial in healthy volunteers completed. Ph2a trial in UC patients initiated in late 2023.
PRECLINICAL
PHASE I
PHASE IIA
PHASE IIB
PHASE III
Phase I Promising phase 2a results have been obtained with ALTB-168. With the same binding domains present on ALTB-268, phase 2a study of PsA of ALTB-268 is under planning.
ALTB-168
PRECLINICAL
PHASE I
PHASE IIA
PHASE IIB
PHASE III
Phase II
Phase 2 Psoriasis trials completed with signs of clinical efficacy achieved.
Phase 2a Psoriatic Arthritis (PsA) and Phase 2a Ulcerative Colitis (UC) trials completed with signs of clinical efficacy demonstrated.
UC and PsA development continued with ALTB-268.
PRECLINICAL
PHASE I
PHASE IIA
PHASE IIB
PHASE III
Phase I
Phase 1 investigator-sponsored front line acute graft versus host disease trial ongoing.
Phase 1b multi-dose steroid/treatment refractory acute graft versus host disease trial completed with sign of clinical efficacy.
Apr, 2024
Publications
top